Navigation Links
Dilon Technologies Leads Molecular Breast Imaging Expansion
Date:2/10/2009

- Clinicians Embrace MBI Technique Breast-Specific Gamma Imaging (BSGI) Resulting in Record 2008 Sales

NEWPORT NEWS, Va., Feb. 10 /PRNewswire/ -- Dilon Technologies, Inc., a leader in molecular breast imaging, today announced record sales for 2008 highlighted by the strongest fourth quarter in the company's history. The company achieved a 35 percent increase in sales from 2007 to 2008 as molecular breast imaging gains nationwide exposure and acceptance.

Breast-Specific Gamma Imaging (BSGI) - a molecular imaging procedure, along with breast MRI, are expected to increase at a compound growth rate of 28 percent over the next five years, according to the Millennium Research Group's U.S. Markets for Women's Health Imaging Systems report. It also states that Dilon Technologies is leading the way to global availability of molecular breast imaging. Dilon's cornerstone product, the Dilon 6800 Gamma Camera is a high-resolution, compact gamma camera optimized to perform BSGI.

"We had a particularly strong finish to the year, breaking through a monthly sales record in December," said Bob Moussa, President and CEO of Dilon Technologies. "Breast imaging centers across the country and around the world are using BSGI to pave the way to effective diagnosis of breast cancer."

BSGI is an adjunctive molecular breast imaging technique to mammography that can see lesions independent of tissue density and discover early stage cancers. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as "hot spots" on the BSGI image.

Dilon's molecular imaging technology is already available in Europe, parts of the Asian-Pacific basin, the Caribbean, and soon to be in Latin America. In addition, Dilon continues to pursue new alliances with companies such as Terason (Terason t3000(TM) Ultrasound System) and PenRad (PenRad Mammography Information System) to help deliver advanced diagnostic solutions to doctors and patients.

"BSGI and our expanded product and service offerings provide critical diagnostic information for physicians to diagnose and treat patients," said Moussa. "More than 50,000 patients have been imaged with BSGI. As we move forward into 2009, we will continue the momentum with the help of physicians worldwide."

About Dilon Technologies

Dilon Technologies, Inc. is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Technologies please visit www.dilon.com.


'/>"/>
SOURCE Dilon Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dilon Technologies Slant15(TM) and LEHR Collimators Enhance Imaging Capabilities
2. Dilon Technologies Signs Amerinet for Breast-Specific Gamma Imaging
3. Dilon Technologies Announces National Agreement with MedAssets
4. Settlement Reached Between Dilon Technologies and Naviscan on Patent Rights
5. Dilon Technologies Appoints New VP of Sales & Business Development
6. Dilon Technologies Explores Improvements in Molecular Breast Imaging
7. China Medical Technologies to Announce Financial Results for the Third Fiscal Quarter Ended December 31, 2008 on March 2, 2009
8. VNUS Medical Technologies to Present at the Roth 21st Annual OC Growth Stock Conference
9. Greenway Medical Technologies and Navicure Form Partnership to Streamline Claims Management Process
10. ReBuilder Medical Technologies, Inc. to Change Name to American Med Tech
11. Advanced Wound Technologies Mid-Atlantic, Inc. Announces Name Change and Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: